NuCana (NASDAQ:NCNA) Stock Falls 2.9% – Here’s Why

NuCana PLC Sponsored ADR (NASDAQ:NCNA) dropped 2.9% on Thursday. The stock traded as low as $0.97 and last traded at $1.02. Approximately 55,147 shares changed hands during trading, a decline of 78% from the average daily volume of 253,137 shares. The stock had previously closed at $1.05.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

NuCana Stock Performance

The company has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.62. The company has a market capitalization of $4.24 million, a price-to-earnings ratio of -0.27 and a beta of 2.30.

NuCana (NASDAQ:NCNA) last issued its earnings results on Thursday, August 13th. The company reported ($0.99) EPS for the quarter, beating analysts’ consensus estimates of ($2.65) by $1.66.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance.

NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers.